Gustavo Mondragon, MD
Cardiovascular Disease · Chula Vista, CANPI 1619080041
Payments from drug & device makers
Across 365 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Esperion Therapeutics, Inc.$851
- Actelion Pharmaceuticals US, Inc.$668
- Novo Nordisk$600
- Amgen$369
- Boehringer Ingelheim$260
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,666100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 103 | $1,649 |
| Esperion Therapeutics, Inc. | 51 | $851 |
| Actelion Pharmaceuticals US, Inc. | 53 | $668 |
| Novo Nordisk | 26 | $600 |
| Amgen | 19 | $369 |
| Boehringer Ingelheim | 10 | $260 |
| Xeris Pharmaceuticals, Inc. | 9 | $201 |
| Dexcom, Inc. | 7 | $166 |
| Lilly USA, LLC | 7 | $158 |
| Medtronic(2 entities) | 8 | $142 |
| Ironwood Pharmaceuticals, Inc | 6 | $132 |
| AstraZeneca | 6 | $122 |
| Bayer | 5 | $114 |
| Merck | 6 | $109 |
| Boston Scientific | 1 | $108 |
| Biotronik Inc. | 3 | $95 |
| Electromed, Inc. | 6 | $93 |
| Radius Health, Inc. | 3 | $84 |
| Regeneron Healthcare Solutions, Inc. | 5 | $80 |
| Scpharmaceuticals Inc. | 2 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $67 |
| GSK | 3 | $65 |
| Travere Therapeutics, Inc. | 3 | $60 |
| Calliditas Therapeutics US Inc. | 2 | $51 |
| Johnson & Johnson | 3 | $50 |
| Insulet Corporation | 2 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $41 |
| Cvrx, Inc. | 1 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Nevro Corp. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $23 |
| Gilead | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
| AbbVie | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Strongbridge US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,679 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 23 | $277,858 |
| EliquisApixaban | 238 | $267,175 |
| EntrestoSacubitril/Valsartan | 147 | $176,192 |
| JardianceEmpagliflozin | 174 | $174,473 |
| OzempicSemaglutide | 141 | $165,712 |
| JanuviaSitagliptin Phosphate | 119 | $119,954 |
| TrulicityDulaglutide | 87 | $100,422 |
| LinzessLinaclotide | 38 | $39,068 |
| FarxigaDapagliflozin Propanediol | 43 | $38,897 |
| LeqvioInclisiran Sodium | 12 | $36,974 |
| XareltoRivaroxaban | 21 | $29,411 |
| NexlizetBempedoic Acid/Ezetimibe | 29 | $25,765 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 40 | $25,618 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,649 |
| RybelsusSemaglutide | 13 | $19,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $668 | $277,85823 claims |
| NovartisEntresto, Leqvio | $1,649 | $213,166159 claims |
| Boehringer IngelheimJardiance, Tradjenta | $260 | $191,155190 claims |
| Novo NordiskOzempic, Rybelsus | $600 | $184,957154 claims |
| MerckJanuvia, Janumet | $109 | $133,327131 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $158 | $111,84998 claims |
| AstraZenecaFarxiga, Brilinta | $122 | $54,53461 claims |
| AbbVieLinzess | $19 | $39,06838 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $851 | $31,56444 claims |
| Johnson & JohnsonXarelto | $50 | $29,41121 claims |
| GSKTrelegy Ellipta | $65 | $21,64933 claims |
| AmgenProlia | $369 | $18,52811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Chula Vista
- Brett BermanChula Vista$1.7M
- Milind ParikhChula Vista$1.6M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.